MUMBAI, Aug 24 (Reuters) - Ranbaxy Laboratories, India's top drugmaker by sales, said on Monday it had final approval from the U.S. Food and Drug Administration to make and market peptic ulcer treatment tablet Glycopyrrolate in two variants.
The tablet is the generic version of Sciele Pharma's Robinul and has annual market sales of $26 million, the Indian firm said in a statement.
Ranbaxy, majority owned by Japan's Daiichi Sankyo, plans to launch the tablet in the December quarter.
(Reporting by Narayanan Somasundaram; Editing by John Mair)
((narayanan.somasundaram@thomsonreuters.com; 91 22 6636 9068; Reuters Messaging narayanan.somasundaram.reuters.com@reuters.net)) Keywords: RANBAXY/GLOCOPYRROLATE (If you have a query or comment on this story, send an email to newsfeedback.asia@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
The tablet is the generic version of Sciele Pharma's Robinul and has annual market sales of $26 million, the Indian firm said in a statement.
Ranbaxy, majority owned by Japan's Daiichi Sankyo, plans to launch the tablet in the December quarter.
(Reporting by Narayanan Somasundaram; Editing by John Mair)
((narayanan.somasundaram@thomsonreuters.com; 91 22 6636 9068; Reuters Messaging narayanan.somasundaram.reuters.com@reuters.net)) Keywords: RANBAXY/GLOCOPYRROLATE (If you have a query or comment on this story, send an email to newsfeedback.asia@thomsonreuters.com) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.